- Alone or with other agents in the management of hypertension.
- Reduction of risk of myocardial infarction, stroke, or cardiovascular death in patients
55 yr who are at high risk for cardiovascular events and are unable to take ACE inhibitors.
55 yr who are at high risk for cardiovascular events and are unable to take ACE inhibitors.Contraindicated in:
Use Cautiously in:
CNS: dizziness, fatigue, headache.
CV: hypotension.
EENT: sinusitis.
F and E: hyperkalemia.
GI: abdominal pain, diarrhea, dyspepsia.
GU: impaired renal function.
MS: back pain, myalgia.
Misc: ANGIOEDEMA.
Drug-Drug:
(Generic available)
Hypertension
Cardiovascular Risk Reduction
Therapeutic Classification: antihypertensives
Pharmacologic Classification: angiotensin II receptor antagonists
Absorption: 42–58% absorbed following oral administration (bioavailability increased in patients with hepatic impairment).
Distribution: Crosses the placenta.
Protein Binding: 99.5%.
Metabolism/Excretion: Excreted mostly unchanged in feces via biliary excretion.
Half-life: 24 hr.
NDC Code*
